Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: An in vivo and in vitro study

Li,Shuai; Han,Zhiyang; Ma,Yong; Song,Ruipeng; Pei,Tiemin; Zheng,Tongsen; Wang,Jiabei; Xu,Dongsheng; Fang,Xiang; Jiang,Hongchi; Liu,Lianxin

doi:10.3892/or.2013.2853

Hydroxytyrosol inhibits cholangiocarcinoma tumor growth: An in vivo and in vitro study

Authors:
- Shuai Li
- Zhiyang Han
- Yong Ma
- Ruipeng Song
- Tiemin Pei
- Tongsen Zheng
- Jiabei Wang
- Dongsheng Xu
- Xiang Fang
- Hongchi Jiang
- Lianxin Liu
View Affiliations

Affiliations: Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China, Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China
Published online on: November 14, 2013 https://doi.org/10.3892/or.2013.2853
Pages: 145-152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a type of digestive tumor that is associated with a high rate of mortality due to the difficulty of early diagnosis and the resistance of this tumor type to chemotherapy. Hydroxytyrosol (HT), which is derived from virgin olive oil (VOO), has recently been reported to inhibit the proliferation of various types of human cancer cells. In the present study, we investigated the effect of HT on CCA. The antiproliferative and proapoptotic effects of HT on CCA were evaluated in the human CCA cell lines TFK-1 and KMBC and the human gallbladder cancer cell line GBS-SD. We also assessed this effect in vivo. We found that 75 µM HT inhibited the proliferation of the TFK-1, KMBC and GBS-SD cell lines. However, 200 µM HT treatment did not affect the proliferation of the human bile duct cell line HIBEpiC. More importantly, HT (250 and 500 mg/kg/day) markedly inhibited the growth of CCA xenografts in mice. G2/M phase cell cycle arrest and apoptosis were observed using flow cytometry and western blotting, and we also noted a time- and dose-dependent inhibition of phospho-ERK, with no changes in total-ERK, during treatment with HT. The present study showed that HT induces cell cycle arrest and apoptosis in vitro and in vivo. These data suggest that HT, which possesses excellent biocompatibility and few side-effects, could be developed as a novel agent against CCA.

View Figures

View References

1	Weinbren K and Mutum SS: Pathological aspects of cholangiocarcinoma. J Pathol. 139:217–238. 1983. View Article : Google Scholar
2	Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar
3	Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, et al: Tumors and tumor-like lesions of the liver and the biliary tract: aetiology, epidemiology and pathology. Pathology of the Liver. MacSween RNM: Churchill Livingstone; London: pp. 711–775. 2002
4	Taylor-Robinson SD, Toledano MB, Arora S, et al: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 48:816–820. 2001.
5	Khan SA, Davidson BR, Goldin RD, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
6	Vauthey JN and Blumgart LH: Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 14:109–114. 1994. View Article : Google Scholar : PubMed/NCBI
7	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
8	Jarnagin WR and Shoup M: Surgical management of cholangio- carcinoma. Semin Liver Dis. 24:189–199. 2004. View Article : Google Scholar
9	Zhang BH, Cheng QB, Luo XJ, Zhang YJ, Jiang XQ, Zhang BH, Yi B, Yu WL, Wu MC, et al: Surgical therapy for hiliarcholangiocarcinoma: analysis of 198 cases. Hepatobiliary Pancreat Dis Int. 5:278–282. 2006.PubMed/NCBI
10	Morise Z, Sugioka A, Tokoro T, et al: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2:58–64. 2010.PubMed/NCBI
11	Iwatsuki S, Todo S, Marsh JW, et al: Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg. 187:358–364. 1998. View Article : Google Scholar : PubMed/NCBI
12	Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 41:5–15. 2005. View Article : Google Scholar : PubMed/NCBI
13	Anderson CD, Pinson CW, Berlin J, Chari RS, et al: Diagnosis and treatment of cholangiocarcinoma. Oncologist. 9:43–57. 2004. View Article : Google Scholar
14	Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
15	Russo GL: Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol. 74:533–544. 2007. View Article : Google Scholar : PubMed/NCBI
16	Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG, et al: Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem. 15:1044–1071. 2008. View Article : Google Scholar
17	Kaefer CM and Milner JA: The role of herbs and spices in cancer prevention. J Nutr Biochem. 19:347–361. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ortega R: Importance of functional foods in the Mediterranean diet. Public Health Nutr. 9:1136–1140. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bartoli R, Fernandez-Banares F, Navarro E, Castella E, et al: Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E₂ synthesis. Gut. 46:191–199. 2000. View Article : Google Scholar : PubMed/NCBI
20	Owen RW, Giacosa A, Hull WE, Haubner R, et al: The anti-oxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer. 36:1235–1247. 2000. View Article : Google Scholar : PubMed/NCBI
21	Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Sanchez-Rovira P, Ramirez-Tortosa MC, et al: Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutr Rev. 68:191–206. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ragione FD, Cucciolla V, Borriello A, Pietra VD, et al: Hydroxytyrosol, a natural molecule occurring in olive oil, induces cytochrome c-dependent apoptosis. Biochem Biophys Res Commun. 278:733–739. 2000. View Article : Google Scholar : PubMed/NCBI
23	Fabiani R, De Bartolomeo A, Rosignoli P, Servili M, et al: Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur J Cancer Prev. 11:351–358. 2002. View Article : Google Scholar : PubMed/NCBI
24	D’Angelo S, Ingrosso D, Migliardi V, Sorrentino A, et al: Hydroxytyrosol, a natural antioxidant from olive oil, prevents protein damage induced by long-wave ultraviolet radiation in melanoma cells. Free Radic Biol Med. 38:908–919. 2005.PubMed/NCBI
25	Han J, Talorete TP, Yamada P, Isoda H, et al: Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology. 59:45–53. 2009. View Article : Google Scholar : PubMed/NCBI
26	Corona G, Deiana M, Incani A, Vauzour D, Dessì MA, Spencer JP, et al: Hydroxytyrosol inhibits the proliferation of human colon adenocarcinoma cells through inhibition of ERK1/2 and cyclin D1. Mol Nutr Food Res. 53:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
27	Saijyo S, Kudo T, Suzuki M, et al: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 177:61–71. 1995. View Article : Google Scholar : PubMed/NCBI
28	Autret A and Martin SJ: Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell. 36:355–363. 2009. View Article : Google Scholar : PubMed/NCBI
29	Nicholson DW and Thornberry NA: Caspases: killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar
30	Kluck RM, Bossy WE, Green DR, Newmeyer DD, et al: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
31	Wang X: The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922–2933. 2001.
32	de Groot RP, Coffer PJ and Koenderman L: Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 10:619–628. 1998.PubMed/NCBI
33	Malemud CJ: Inhibitors of stress-activated protein/mitogen activated protein kinase pathways. Curr Opin Pharmacol. 7:339–343. 2007. View Article : Google Scholar : PubMed/NCBI
34	Morrison DK and Davis RJ: Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 19:91–118. 2003. View Article : Google Scholar : PubMed/NCBI
35	Rennefahrt U, Janakiraman M, Ollinger R, Troppmair J, et al: Stress kinase signaling in cancer: fact or fiction? Cancer Lett. 217:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
36	Prouillet C, Mazière JC, Mazière C, Wattel A, Brazier M and Kamel S: Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem Pharmacol. 67:1307–1313. 2004. View Article : Google Scholar
37	Yin F, Giuliano AE, Law RE and Van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 21:413–420. 2001.PubMed/NCBI
38	Wruck CJ, Claussen M, Fuhrmann G, Römer L, et al: Luteolin protects rat PC12 and C6 cells against MPP⁺ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm (Suppl). 72:57–67. 2007. View Article : Google Scholar : PubMed/NCBI